Sabuwar masana'antar tantancewar in vitro tana shigowa cikin wani lokaci na ci gaba cikin sauri

Novel coronavirus ciwon huhu sabon ciwon coronavirus ciwon huhu shine mafi mahimmancin fifiko tsakanin abubuwan fifiko. Labarin masana'antar cututtukan huhu na huhu (IVD) zai bunkasa cikin sauri tare da saurin haɓaka sabbin fasahohi daban-daban da ƙaddamar da sabon kamuwa da ciwon huhu. Ana tsammanin ya zama ɗayan kasuwanni masu haɓaka da sauri a cikin masana'antar kayan aikin likita a gaba.

Sabuwar fasaha, sabon yanayi da sabon buƙata suna buɗe sabon sarari

Tare da saurin ci gaban kimiyyar kere-kere, sikelin kasuwa na masana'antar binciken in vitro na duniya yana girma cikin sauri. Dangane da bayanan kasar Sin a cikin hanyar binciken in vitro (caivd), a cikin 2013, girman kasuwa na masana'antar binciken in vitro ta duniya ya kai kimanin dala biliyan 60, kuma ya zarce dala biliyan 80 a shekarar 2019, tare da matsakaita yawan ci gaban shekara-shekara na 6%. Ana tsammanin girman kasuwar zai wuce dalar Amurka biliyan 90 a shekarar 2020 (duba hoto na 1 don 

fbg

Dangane da ka'idojin ganowa da hanyoyi, ana iya raba shi zuwa manyan fannoni shida: rigakafin rigakafin cuta, binciken kwayoyin halitta, binciken jini, binciken kwayoyin, binciken kwayoyin cuta da kuma ganowa nan take (POCT). Daga ci gaban ci gaban kasuwar bincike ta duniya a cikin vitro, a cikin recentan shekarun nan, rabon kasuwa na binciken ƙwayoyin cuta na asibiti da samfuran rigakafin cutar ya ɗan ragu, yayin da rabon kasuwar gano asalin acid, microbiology, histology da cytometry mai gudana ya karu kowace shekara, tare da matsakaicin matsakaicin haɓakar haɓaka shekara fiye da 10%. A cikin 2019, rigakafin rigakafin cuta yana da kasuwa mafi girma, wanda ya kai kashi 23%, sannan bincikar kwayoyin cuta, ya kai 17% (duba hoto na 2 don cikakkun bayanai).

kjd3

A cikin 'yan shekarun nan, sabbin fasahohi da sifofin masana'antar binciken in vitro suna ta bayyana. Fasahar binciken kwayar halittar da tsara ta tsara biyu (NGS) ke wakilta, samfuran gano lokaci na ainihi wanda kwakwalwan microfluidic ke wakilta, da sabbin fasahohi da samfuran zamani kamar kula da lafiya na zamani da kuma kula da lafiya daidai, wanda babban bayanai da Intanet suka wakilta, sun buɗe sabon ɗaki don masana'antar bincike a cikin injin. Tare da ci gaba da haɓaka fasahar bincike a cikin vitro da kuma fa'idar amfani da alaƙa da ƙarancin kimiyya da fasaha, kasuwar binciken in vitro ta duniya za ta ci gaba da haɓaka ci gaba. Bugu da kari, yawan mutanen duniya na karuwa, kuma yawan kamuwa da cututtukan da ake fama da su, da cutar kansa da sauran cututtuka na karuwa. Hakanan yana haɓaka ci gaba da ci gaba da kasuwar in vitro.

Gaggawar saurin tsufa da yawan jama'a, fasahar kere-kere da kirkirar manufofi, masana'antar binciken in vitro a kasar Sin tana ci gaba da bunkasa. A cikin 'yan shekarun nan, masana'antar gano cikin gida ta in vitro ta bunkasa cikin sauri, wasu kamfanonin cikin gida sun samu nasarori a fannin kere-kere, kuma wasu kamfanonin cikin gida sun tashi cikin sauri saboda tsananin bukatar kasuwar cikin gida. Bugu da kari, a cikin 'yan shekarun nan, kasar Sin ta fitar da jerin manufofi a jere don tallafawa ci gaban masana'antar gano cutar in vitro. Misali, akwai daidaitattun manufofin tallafi a cikin shekaru 13 na shekaru biyar don na'urar kimiyya da kere-kere na kere-kere na kere-kere, shirin 13th na shekaru biyar game da kere-kere da kere-kere na kasar Sin da kuma shirin samar da lafiya na 2030 na kasar Sin, wanda hakan ke kara karfafa mahimmancin masana'antu.

 

Kasuwa masu tasowa suna da dama

Gabaɗaya, ci gaban kasuwar IVD ta duniya ba ta da daidaito. Daga mahangar rarraba yanki, Arewacin Amurka, Yammacin Turai da sauran yankuna masu ci gaban tattalin arziki suna da sama da kashi 60% na kasuwar; ta fuskar kasuwar kasuwancin, kusan rabin kason kasuwar ana ɗaukar su Roche, Abbott, Siemens da Danaher. China kasuwa ce mai tasowa ta masana'antar tantancewar in vitro, wanda ke cikin lokacin haɓaka cikin sauri a yanzu kuma ana iya tsammanin sa a gaba.

A halin yanzu, ƙasashe masu ci gaba irin su Arewacin Amurka da Yammacin Turai suna da fiye da kashi 60% na kasuwar binciken in vitro. Koyaya, ƙasashe masu ci gaba da kasuwannin yanki sun shiga matakan girma tare da ci gaba mai sauƙi da haɓaka mai sauƙi. A cikin ƙasashe masu tasowa, azaman masana'antun da ke tasowa, cutar cikin inabi tana da halaye na ƙananan tushe da ƙimar girma. Ana tsammanin cewa a cikin kasuwannin da ke zuwa waɗanda China, Indiya da sauran ƙasashe da yankuna ke wakilta, haɓakar haɓakar in vitro kasuwar bincike zata kasance a 15% ~ 20%. Kasuwa mai tasowa zata zama ɗayan mafi yuwuwar yankunan masana'antar binciken in vitro.

mka2

Masana'antar bincikar cutar in vitro ta kasar Sin ta fara ne a karshen shekarun 1970 kuma yanzu tana cikin wani lokaci na samun ci gaba cikin sauri. A cikin 2019, sikelin kasuwa na masana'antar bincikar in vitro ta China ya kusan yuan biliyan 90, tare da matsakaicin haɓakar haɓakar haɓakar shekara fiye da 20%. A cikin shekaru 10 da suka gabata, fiye da 20 na cikin masana'antar binciken in vitro sun sami nasarar IPO, kuma Mindray medical, Antu biological, BGI da Wanfu biological sun zama manyan kamfanoni a sassan su. Wasu abubuwa da aka yi amfani da su sosai (kamar su binciken ƙwayoyin cuta da ganewar asali) sun kai matakin ci gaba na duniya a daidai wannan lokacin. Kama da kasuwar duniya, Roche, Abbott, Danaher, Siemens da hysenmecon suna da sama da kashi 55% na kasuwar IVD ta China. Kamfanoni na kasashe daban-daban suna amfani da fa'idodin su a cikin kayayyaki, fasaha da sabis don ci gaba da haɓaka saka hannun jari a China, musamman a manyan makarantun sakandare na cikin gida da sauran manyan kasuwanni, inda farashin yake gaba ɗaya fiye da na irin waɗannan kayayyakin na cikin gida. A cikin littafin rigakafin cututtukan huhu na coronavirus na wannan shekara da sarrafawa, ƙananan in-vitro kamfanonin bincike suna nuna idanuwansu masu haske. Kamfani na gwaji na uku ya inganta matsayinsa a tsarin likitanci, kuma ana sa ran zai gudanar da karin aikin gano cutar.

 

A cikin in vitro reagents na sakewa sune kayan masarufi, kuma buƙatar kasuwar jari ba zata taƙaita ba. Kasuwar bincikar cikin gida ba ta kai “rufi” ba. Har yanzu akwai sauran fannoni da yawa da ba za a wadatar da su ba, kuma masana'antar za ta ci gaba da daidaito da saurin ci gaba a nan gaba.

 

Kyakkyawan tsammanin ga manyan sassa uku

A zamanin da annoba ta wuce, masana'antar binciken in vitro na kasar Sin za ta shiga wani lokaci na ci gaba mai karfi a cikin binciken kwayoyin, rigakafin rigakafin cutar da kuma ganowar nan take.

 

Binciken kwayar halitta

A halin yanzu, bunkasuwar kasuwa na masana'antar gano kwayoyin halittu a kasar Sin tana da sauri, yawan masana'antun ba shi da yawa, gibin fasahar dake tsakanin kamfanonin cikin gida da na kasashen waje kadan ne, kuma kowane kamfani yana da nasa kwarewar.

 

Bisa kididdigar da aka yi, a cikin shekarar 2019, ma'aunin kasuwar masana'antar tantance kwayoyin kwayoyin kasar Sin ya kai yuan biliyan 11.58; matsakaicin girman haɓakar shekara-shekara daga 2011 zuwa 2019 zai kai kashi 27%, kusan ninki biyu na haɓakar duniya. A cikin kasuwar binciken kwayar halittar kasar Sin, kamfanonin da ke samun kudi daga kasashen waje sun kai kashi 30% na kasuwar, galibi sun fi mayar da hankali ne daga hakar ma'adanin masana'antu, tare da kayayyakin Roche, Abbott na PCR mai yawa da kuma mai bi masa IL Lumina shine wakilin; Kamfanoni na gida suna da kashi 70% na kasuwar samfur, kuma kasuwancin su yafi mai da hankali ne akan abubuwan bincike na PCR da kuma ayyukan bincike na ngs. Kamfanonin wakilcin sun hada da Biology na Kaipu, aide biology, Huada gene, berry gene, Zhijiang biology, Daan gene, da sauransu.

 

Akwai mahalarta da yawa a cikin kasuwar binciken ƙwayoyin cuta a cikin Sin, kuma ƙididdigar masana'antu ba ta da yawa. Babban dalilin wannan lamarin shine cewa bukatun asibiti da ke cikin binciken kwayar suna da yawa kuma masu rikitarwa, kuma kowane mahalarcin kasuwa yana da halaye na fasaha da yankuna na gwaninta, don haka yana da wahala a cika dukkan kasuwancin, don haka yana da wahala samarwa babban tsarin gasa.

 

Fasahar binciken kwayar halitta yafi kunshe da PCR, kifi, jerin jeren halitta da gutsurin jiji. A cikin dogon lokaci, sararin ci gaba na kera kere-keren fasaha ya fi fadi, amma farashin sa ya fi yawa. Fasahar PCR har yanzu ita ce fasaha ta al'ada a fagen binciken kwayar halitta. Don yin aiki mai kyau a cikin rigakafin rigakafin cuta da sarrafawa, yawancin masana'antun binciken ƙwayoyin cuta na gida sun ci gaba da haɓaka sabbin kayan aikin gano coronavirus nucleic acid, kuma mafi yawan waɗannan kayan aikin suna amfani da fasahar PCR mai kyalli mai haske, wanda ke taka muhimmiyar rawa a rigakafin annoba da sarrafawa, kuma yana motsa dukkanin masana'antar binciken ƙwayoyin cuta don samun kyakkyawan fata.

Immunodiagnosis

A halin yanzu, kasuwar rigakafin rigakafi ita ce kasuwa mafi girma a cikin masana'antar binciken in vitro a cikin China, wanda ya kai kimanin 38% na duka kasuwar binciken in vitro.

mak1

Fiye da kashi 60% na kason kasuwar rigakafin rigakafin cutar a cikin ƙasar ta shaƙatawa ne daga kamfanonin waje, yayin da kashi 30% kawai na kason kasuwannin ƙananan kamfanoni kamar su Mindray medical, Mike biological, Antu biological, da dai sauransu suke shagaltar, kuma masana'antar maida hankali yana da yawa. Kamfanonin da ke ba da tallafi na ƙasashen waje suna da kashi 80% ~ 90% na ƙarshen kasuwar kasada na rigakafin rigakafin rigakafi a cikin Sin tare da fa'idodin fasahar samfurin su na shekaru da yawa, kuma abokan cinikin su galibi manyan makarantu ne; kamfanoni na cikin gida suna hanzarta aiwatar da sauye-sauye na cikin gida ta hanyar fa'idar aiwatar da farashi da daidaita reagents.

 

Gano kai tsaye

Kasuwa na ainihin lokacin gano cutar ta China ya fara ne da wuri, kuma sikelin kasuwar gabaɗaya ba ta da yawa. Koyaya, a cikin 'yan shekarun nan, yawan ci gaban kasuwa koyaushe ana kiyaye shi a 10% ~ 20%, wanda ya fi girma ƙimar duniya girma na 6% ~ 7%. A cewar bayanan, a cikin shekarar 2018, kasuwar gano ainihin lokacin kasar Sin za ta kai yuan biliyan 6.6, inda za ta kai kimanin Yuan biliyan 7.7 a shekarar 2019; Roche, Abbott, merier da sauran masana'antun da ke ba da kuɗaɗen waje za su sami babban matsayi a cikin babbar kasuwar ƙididdigar ƙasar ta Sin ta ainihi, tare da rabon kasuwa kusan 90%; Kamfanoni na cikin gida suna tafiya a hankali a hankali tare da fa'idodi da ƙwarewar fasahar su.

 

Ganowar kai tsaye na iya samar da sakamako cikin sauri, wanda ba'a iyakance shi ta shafin gwaji ba, amma kuma yana buƙatar ƙwarewar ƙwararrun ƙwararrun masu aiki. Ya dace da cibiyoyin kiwon lafiya na tushen, da kuma manyan asibitoci, kamar gaggawa, marasa lafiya, aikin riga-kafi, aikin kula da cututtukan da ba a san su ba, lura da kamuwa da cututtukan da ba a sani ba, gano hanyar shiga ta hanyar shiga, duba masu fita da fitowar mutane da sauran yanayin. . Sabili da haka, dacewa, ƙarami kuma ya dace da saurin ganewar asali na kayan gwajin gwaji na ainihi zai taka muhimmiyar rawa wajen haɓaka masana'antar ganewar in vitro a nan gaba. A halin yanzu, masana'antar gano ainihin lokaci a kasar Sin sun hada da Wanfu biology, Jidan biology, Mingde biology, Ruilai biology, Dongfang gene, Aotai biology, da sauransu.

 

Ta hanyar yin la’akari da tasirin tasirin annobar da kuma ci gaban kasuwar, zamu iya gano cewa yanayin ci gaban kasuwar da kuma hangen nesan kwayoyin, gano rigakafin cutar da kuma ganowar kai tsaye suna da kyau. Tare da mahimmiyar rawar da yake takawa a rigakafin cutar da sarrafawa, a cikin cutar ta vitro zai zama mafi damuwa da ganewa ta kasuwa, kuma zai kasance ɗayan mahimman wurare a cikin masana'antar kayan aikin likita a cikin fewan shekaru masu zuwa.


Post lokaci: Dec-18-2020